abstract |
Novel antagonists of MCP proteins, particularly MCP-1 proteins, can be obtained by generating MCP variants in which the GAG binding site located at the N-terminus of the MCP protein has been removed with non-conservative substitutions. The compounds prepared according to the invention can be used for the treatment or prevention of diseases related to the undesirable activity of MCP proteins, such as inflammatory diseases, autoimmune diseases, vascular diseases, cancer. |